stoxline Quote Chart Rank Option Currency Glossary
  
MyMD Pharmaceuticals, Inc. (MYMD)
2.01  0.03 (1.52%)    05-28 16:00
Open: 2.06
High: 2.06
Volume: 29,841
  
Pre. Close: 1.98
Low: 1.99
Market Cap: 5(M)
Technical analysis
2024-05-28 4:24:16 PM
Short term     
Mid term     
Targets 6-month :  3.3 1-year :  3.93
Resists First :  2.83 Second :  3.36
Pivot price 2.29
Supports First :  1.97 Second :  1.63
MAs MA(5) :  2.01 MA(20) :  2.51
MA(100) :  3.42 MA(250) :  16.02
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  2.7 D(3) :  2.3
RSI RSI(14): 35.2
52-week High :  63.9 Low :  1.97
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ MYMD ] has closed above bottom band by 21.7%. Bollinger Bands are 35.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.06 - 2.08 2.08 - 2.09
Low: 1.96 - 1.98 1.98 - 1.99
Close: 1.99 - 2.01 2.01 - 2.03
Company Description

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Headline News

Tue, 21 May 2024
MyMD Pharmaceuticals Secures Strategic Investments - citybiz

Tue, 21 May 2024
MyMD Pharmaceuticals Secures Strategic Investments - Investing News Network

Tue, 09 Apr 2024
Why Is MyMD Pharmaceuticals (MYMD) Stock Up 35% Today? - InvestorPlace

Mon, 08 Apr 2024
MyMD Pharmaceuticals Enhances Governance and Financing Structure - TipRanks.com - TipRanks

Tue, 05 Mar 2024
MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing - Yahoo Finance

Tue, 13 Feb 2024
MyMD Pharmaceuticals Announces Reverse Stock Split To Maintain Nasdaq Listing - XM

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 2 (M)
Shares Float 2 (M)
Held by Insiders 7.3 (%)
Held by Institutions 8.3 (%)
Shares Short 214 (K)
Shares Short P.Month 109 (K)
Stock Financials
EPS -5.33
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.05
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -57.8 %
Return on Equity (ttm) -29.2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -13 (M)
Levered Free Cash Flow -5 (M)
Stock Valuations
PE Ratio -0.38
PEG Ratio 0
Price to Book value 0.33
Price to Sales 0
Price to Cash Flow -0.34
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android